Obsessive-Compulsive Disorder Pipeline Review, H1 2019 Report Featuring Addex Therapeutics, Amorsa Therapeutics, Biohaven Pharmaceutical, & Omeros – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Obsessive-Compulsive
Disorder – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Obsessive-Compulsive Disorder – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Obsessive-Compulsive Disorder (Central Nervous System), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline
guide also reviews of key players involved in therapeutic development
for Obsessive-Compulsive Disorder and features dormant and discontinued
projects. The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 4 and
1 respectively. Similarly, the Universities portfolio in Phase I stages
comprises 1 molecule, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Obsessive-Compulsive Disorder (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for
  Obsessive-Compulsive Disorder (Central Nervous System) by companies
  and universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in
  Obsessive-Compulsive Disorder (Central Nervous System) therapeutics
  and enlists all their major and minor projects.
• The pipeline guide evaluates Obsessive-Compulsive Disorder (Central
  Nervous System) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Obsessive-Compulsive Disorder (Central Nervous
  System).

Companies Mentioned

• Addex Therapeutics Ltd
• Amorsa Therapeutics Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Omeros Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6vwbqh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Disorders Drugs, Anxiety
Drugs